Antonio SG, et al. - Researchers investigated how SGLT2 inhibitors could impact all‐cause mortality, by performing this meta‐analysis. They also explored variations across different trials and molecules of the class. All randomized clinical trials with treatment span more than 52 weeks, including at least 100 patients in each arm, and comparing a SGLT2 inhibitor with any comparator or placebo, were included. Experts analyzed 21 eligible trials. Findings revealed that a reduction in all‐cause mortality was brought about by treatment with SGLT2 inhibitors. In meta‐regression analyses, treatment impact was found to be significantly directly related only to proportion of Asian people enrolled, and an inverse correlation was identified with the proportion of Caucasian patients.